M
Mind Medicine (MindMed) Inc. (MNMD)
NMS – Real vaqt narxi. Valyuta: USD
15.02
+0.15 (1.01%)
Yopilishda: Jan 14, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
15.02
+0.15 (1.01%)
Yopilishda: Jan 14, 2026, 4:00 PM EDT
Mind Medicine (MindMed) Inc. – bu miya salomatligi buzilishlarini davolash uchun yangi mahsulotlarni ishlab chiqayotgan klinik bosqichdagi biofarmatsevtika kompaniyasidir. Kompaniyaning asosiy mahsulot nomzodlari orasida MM120, bu umumiy bezovtalik va diqqat etishmasligi giperfaollik buzilishi (ADHD) ni davolash uchun 3-bosqichda; va MM402, bu avtizm spektrining buzilishi (ASD) ning asosiy alomatlarini davolash uchun I bosqich klinik sinovlarida bo'lgan 3,4-metilendioksimetamfetaminning R-enantiomeri mavjud. Mind Medicine (MindMed) Inc.ning shtab-kvartirasi Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer |
| Dr. Gregg Pratt Ph.D. | Chief Regulatory & Quality Assurance Officer |
| Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor |
| Mr. Leonard Latchman | Co-Founder |
| Mr. Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Peter Mack | Senior Vice President of Pharmaceutical Development & Operations |
There is no data to display
| Mr. Robert Barrow | CEO & Director |
| Ms. Beth Calitri | Vice President of Corporate Communications |
| Ms. Brandi L. Roberts CPA, M.B.A. | Chief Financial Officer |
| Ms. Stephanie Fagan | Chief Corporate Affairs Officer |